UK markets close in 7 hours 37 minutes

Heron Therapeutics, Inc. (0J4V.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.5783-0.1217 (-4.51%)
As of 07:05PM BST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.71
52-week change 323.56%
S&P500 52-week change 321.08%
52-week high 33.1950
52-week low 30.0000
50-day moving average 32.4101
200-day moving average 31.5677

Share statistics

Avg vol (3-month) 312.41k
Avg vol (10-day) 36.54k
Shares outstanding 578.02M
Implied shares outstanding 6N/A
Float 8122.04M
% held by insiders 10.94%
% held by institutions 176.02%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -87.02%
Operating margin (ttm)-28.39%

Management effectiveness

Return on assets (ttm)-24.56%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)127.04M
Revenue per share (ttm)0.92
Quarterly revenue growth (yoy)14.00%
Gross profit (ttm)N/A
EBITDA -90.12M
Net income avi to common (ttm)-110.56M
Diluted EPS (ttm)-2.2930
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)80.41M
Total cash per share (mrq)0.54
Total debt (mrq)179.63M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.37
Book value per share (mrq)-0.23

Cash flow statement

Operating cash flow (ttm)-58.79M
Levered free cash flow (ttm)-16.84M